BiTE: The Future of Cancer Treatment through Clinical Trials - OHC

Description

Bi-specific T-cell engagers (BiTE) is a groundbreaking therapeutic strategy that harnesses the power of the immune system to target and eliminate cancer cells.

David M. Waterhouse, MD, MPH - OHC

OHC, Specialists in the Treatment of Adult Cancers and Blood Disorders, Author at OHC - Oncology Hematology Care - Page 2 of 23

American Society for Clinical Pharmacology and Therapeutics - 2016 - Clinical Pharmacology & Therapeutics - Wiley Online Library

$ 24.50USD
Score 4.5(105)
In stock
Continue to book